Aligos Therapeutics Inc

Research Aligos Therapeutics Inc (ALGS) on Bullrun: market cap USD 33.60M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerALGS
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 33.60M
• Financial periodFY2025
• RevenueUSD 2.19M
• Revenue growth-39.5%
• Net income-USD 24.19M

Valuation Snapshot

latest market cap is USD 33.60M.

About Aligos Therapeutics Inc

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial;

Frequently asked questions

What is Aligos Therapeutics Inc's market cap?

Aligos Therapeutics Inc's market capitalization is USD 33.60M.

What does Aligos Therapeutics Inc do?

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases.